Scotiabank Has Lowered Expectations for Kura Oncology (NASDAQ:KURA) Stock Price

Kura Oncology (NASDAQ:KURA) had its target price lowered by Scotiabank from $18.00 to $10.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “sector perform” rating on the stock. Scotiabank’s target price would suggest a potential upside of 28.53% from the stock’s current price.

Other equities analysts also recently issued reports about the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research note on Monday, December 9th. Bank of America dropped their target price on Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research report on Friday, November 22nd. TD Cowen reiterated a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. UBS Group assumed coverage on Kura Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective on the stock. Finally, HC Wainwright lifted their target price on shares of Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $27.38.

Kura Oncology Stock Performance

Shares of KURA opened at $7.78 on Wednesday. The company has a market capitalization of $605.00 million, a PE ratio of -3.30 and a beta of 0.81. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The company’s 50 day moving average price is $11.93 and its 200 day moving average price is $17.01. Kura Oncology has a 52 week low of $7.70 and a 52 week high of $24.17.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. nVerses Capital LLC bought a new position in shares of Kura Oncology in the third quarter worth about $25,000. Point72 DIFC Ltd acquired a new stake in Kura Oncology in the 3rd quarter valued at approximately $146,000. Quarry LP bought a new position in Kura Oncology in the 2nd quarter worth approximately $196,000. Erste Asset Management GmbH bought a new stake in shares of Kura Oncology in the third quarter valued at approximately $215,000. Finally, Bellevue Group AG grew its stake in shares of Kura Oncology by 36.0% in the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock worth $266,000 after acquiring an additional 3,600 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.